Skip to main content
OpenTrials
Completed

NCT Number: NCT00410852

Efficacy and Safety of Three Insulin Protocols in Medical Intensive Care Unit Patients

To evaluate the efficacy and safety of three insulin algorithms in medical ICU patients (MICU).

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Complexo Hospitalar UNIMED, Joinville, Santa Catarina, Brazil

Loading trial locations.

About this study

Strict glycemic control has been recommended for critically ill patients. However, its implementation may face difficulties with increased nursing workload, inadequate glucose control and higher risk of hypoglycemia.

We designed a computer guided protocol to adjust endovenous insulin infusion aiming glucose levels between 100mg/dl and 130 mg/dl. This trial evaluates the efficacy and safety of this protocol (algorithm A), compared to a standard endovenous insulin infusion protocol (algorithm B) and a conventional subcutaneous insulin protocol (algorithm C).

Methods : MICU patients with at least one blood glucose ≥ 150 mg/dL and who are on mechanical ventilation, or had SIRS, or are admitted because of trauma or burn will be randomized to one of the following treatments: algorithm A - continuous insulin infusion with adjustments guided by hand held device or desktop software targeting glucose levels between 100mg/dL-130mg/dL; algorithm B - continuous insulin aiming glucose levels between 80mg/dl-110mg/dl using Van den Berghe's insulin protocol; algorithm C - conventional treatment - intermittent subcutaneous administration of insulin if blood glucose levels exceeds 150mg/dL; insulin will be administered as IV boluses in hypotensive patients.

The randomization list was generated in blocks of six by computer software. Patients will be randomly assigned in a 1:1:1 ratio to have their glucose controlled by one of the three insulin algorithms with the use of a central, computerized system accessed by Internet, permitting concealment of allocation list. Randomization will be stratified according to study site.

The study is planned to enroll 165 patients in order to have 80% power to detect a 20mg/dl difference in blood glucose means between groups, assuming standard deviation equal to 33 mg/dl and two-tailed alpha equal to 0.05. Efficacy will be measured by the mean of patients' median blood glucose and safety measured by the incidence of hypoglycemia (≤40 mg/dL). Analysis will follow the intention-to-treat principle.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Criteria 1, 2 and 3 must be present:
  • Clinical patients admitted to an Intensive Care Unit
  • At least one blood glucose measurement >= 150 mg/dL (capilar, venous or arterial blood)
  • At least one of the following:
  • Patient on mechanical ventilation for an acute process, with expected duration of mechanical ventilation of at least 24 hours
  • Polytrauma patients
  • Severe burn patients
  • Systemic Inflammatory Response Syndrome (modified criteria), with at least three of the following: core temperature >=38°C or <=36°C; heart rate >=90 beats/min, except in patients with a medical condition or receiving a medication known to prevent tachycardia; respiratory heart rate >= 20 breaths/min or a PaCO2 <=32mmHg, or the use of mechanical ventilation for an acute process; white-cell count of >=12.000/mm3 or <=4.000/mm3 or a differential count showing >10% percent immature neutrophils

Exclusion criteria

  • Age < 21 years
  • Surgical patients (surgery less than 24hs before admission to ICU)
  • Diabetic ketoacidosis
  • Non-ketotic hyperosmolar state
  • Patients with defined diagnosis of brain death
  • Moribund state in which death is perceived to be imminent

Treatment and study plan

Computer-assisted IV insulin infusion protocol (algorithm A)

Procedure

Computer assisted insulin protocol (CAIP), with continuous intravenous insulin adjustments aiming blood glucose levels between 100 mg/dl and 130 mg/dl.

Leuven Strict glycemic control protocol (Algorithm B)

Procedure

Leuven protocol: continuous intravenous insulin infusion aimiming blood glucose levels between 80mg/dl and 110mg/dl.

Conventional Intermittent Insulin Protocol (Algorithm C)

Procedure

Conventional treatment: intermitent subcutaneous insulin according to a sliding scale, starting with blood glucose levels higher than 150mg/dl.

Primary outcomes

  1. Efficacy: mean of patients' median blood glucose during ICU stay

    Time frame: ICU Stay

  2. Safety: incidence of hypoglycemia (≤40 mg/dL)during ICU stay

    Time frame: ICU stay

Secondary outcomes

  1. Death from any cause

    Time frame: ICU and in-hospital

  2. ICU and hospital length of stay

    Time frame: ICU and in-hospital

  3. Five-day variation in SOFA score

    Time frame: Five days

  4. 90-day health status

    Time frame: 90 days

  5. Days on mechanical ventilation

  6. Initiation of dialysis

  7. Days on antibiotics

  8. Days on inotropic of vasopressor support

  9. Necessity of red blood cell transfusions

  10. Bilirubin peak

  11. Platelets through

Sponsors and collaborators

Lead sponsor

Hospital Israelita Albert Einstein

Other

Collaborators

  • Fundação de Amparo à Pesquisa do Estado de São Paulo

Registry information

Official study title

Randomized Study to Evaluate the Efficacy and Safety of Two Endovenous Insulin Protocols and a Subcutaneous Insulin Protocol in Critically Ill Patients

Important dates

Study start
2005
Study completion
2007
First posted
Dec 13, 2006
Registry last updated
Nov 2, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.